Healthcare

Jim Frates directs the Finance and Corporate Communications departments at Alkermes. During his tenure, Alkermes has raised substantial public capital and acquired the pulmonary drug delivery company, Advanced Inhalation Research, Inc. (AIR®). Jim was previously a vice president in charge of the East Coast Life Sciences Practice at Robertson Stephens & Company, Inc., and also worked in healthcare investment banking at Morgan Stanley & Company, Inc. As a Harvard College Fellow, he spent a year teaching secondary school at the Royal Shrewsbury School in the United Kingdom. Jim currently serves as audit committee chairman on the board of directors for GPC Biotech of Germany and as a national chairperson of the Association of Bioscience Financial Officers. He holds a BA in government from Harvard College and an MBA from the Harvard Graduate School of Business Administration.

Anula Jayasuriya is a life science venture capitalist. She is the co-founder of the "Evolvence India Life Science Fund" (EILSF), established in 2006 to make investments in pharmaceutical, biotechnology, medical device and related contract service companies based in India. The fund has had an initial closing of US $50 million and made its first investment. She was previously a partner with Skyline Ventures in Palo Alto, and prior to that with the German-US venture capital firm TVM, in San Francisco.

Anula's expertise consists of a unique combination of business, basic science and medical knowledge. Her prior positions include VP-Corporate development at Genomics Collaborative Inc., and Vice President, Global Drug Development at Hoffman-La Roche for opportunistic infections in AIDS and Transplantation.

Anula received a BA from Harvard summa cum laude, and an MD and PhD (in Microbiology and Molecular Genetics) from Harvard Medical School. She interned in Pediatrics at Boston Children's Hospital and received an MBA with distinction from Harvard Business School. Anula also has a M. Phil. in pharmacology from the University of Cambridge, England.

David Green graduated from Oxford University, England in 1985 with an honors degree in physics. From 1985 to 1989 he was a brand manager for consumer goods such as Lux and Shield soaps for Lever Brothers (Unilever) in London. In 1989 he moved to the USA and graduated with distinction from Harvard Business School in 1991.

From 1991 to 1995 he was a strategy consultant with Monitor Company in Cambridge, MA and Johannesburg, South Africa. Corporate strategy work included profit and revenue growth initiatives for global clients in the aerospace, retail, life insurance and platinum mining industries. The South African work was advising the newly democratic government on national competitiveness (based on Porter's Competitive Advantage of Nations) and increasing GDP growth rate. He personally presented the work to the president and the cabinet. In addition, David ran all of Monitor's worldwide training programs.

In late 1995 David returned to the USA and put together the venture-backed deal that created Harvard Bioscience (which began as Harvard Apparatus at Harvard Medical School in 1901) becoming co-founder, president and a director. Harvard Bioscience's products are used to advance life science research at virtually all pharmaceutical and biotechnology companies and research universities worldwide. Their customers include two Nobel prize winners and breakthrough scientific research using our instruments has been published in Nature (high-throughput drug discovery on nematode worms) and on the front cover of Nature Biotechnology (malaria eradication) and Transplantation (human islet transplantation for treating Type 1 diabetes). Through a combination of organic growth and over twenty acquisitions Harvard Bioscience has grown from $9M in revenues in 1996 to approximately $90M in 2006 and is highly profitable. Harvard Bioscience went public in December 2000. In 2004 Harvard Bioscience was ranked number three for revenue growth in the Boston Globe 100 index of publicly traded Massachusetts companies. In 2005 Harvard Bioscience was named one of America's Top 25 Fastest Growing Technology Companies by Forbes Magazine. David is a co-inventor on the patent Photoacoustic Spectroscopy Sample Array Vessel.

Kent Thiry, MBA 1983 is Chairman and CEO of DaVita, Inc., the largest independent provider of dialysis services in the United States provider. They are located in 42 states and the District of Columbia, serving approximately 103,000 patients

Kent Thiry has been Chairman and CEO of Davita, Inc. since October 1999. DaVita is a provider of integrated dialysis services for patients suffering from chronic kidney failure. The company’s more than 27,000 teammates work in over 1,300 kidney dialysis centers spread across the U.S. Current annual revenues are over $5 Billion. DaVita cares for approximately 100,000 dialysis patients in the U.S. every week, almost one (1) out of every three (3) in America.

Kent serves on the Board of Directors of Varian Medical Systems, Inc. Varian Medical Systems, Inc. serves the medical equipment market as the world's leading manufacturer of integrated radiotherapy systems for treating cancer and the premier supplier of X-ray tubes and flat panels for diagnostic imaging applications. Prior Board seats include the Chairmanship of Oxford Health Plans.

Kent served as a Partner at Bain & Company from 1987-1991.

In May 2005, Kent received the Adaptive Business Leaders (ABL) 2005 "Leadership in Innovation" Award. The ABL award recognizes DaVita's innovative approach to building a culture of teamwork through a sense of community. His management philosophy has been discussed in various forums, including a Stanford Business School Case Study, the Wall Street Journal and Modern Healthcare.

Kent earned his BA in Political Science, with Distinction and Phi Beta Kappa, from Stanford University in 1978. He earned his MBA, with Honors, from Harvard Business School in 1983, where he was also elected to the Century Club.

Kent was raised in Wisconsin. He has two children, Matthew and Christina. His wife, Denise O'Leary, is a director of Medtronic and US Airways Group, Inc. She is also a member of the Stanford University Board of Trustees, Chair of the Stanford Board Committee for the Stanford Medical Center and a director of Stanford Hospitals and Clinics, where she was chair of the board from 2000 through 2005. She is Chair of the Corporation for Supportive Housing. She is a former venture capital partner at Menlo Ventures and formerly a director of Alza, Del Monte and Chiron Corporation.